Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we examine the plush pay packages of health care’s top CEOs in 2024. Also, we discuss Stealth BioTherapeutics’ efforts to rally support behind its Barth syndrome drug, and hear more from the Broad’s David Liu.
Health care CEOs cash in despite weak stock growth
The biggest companies in health care underwhelmed Wall Street last year, but their CEOs still raked in record pay, an analysis of corporate filings from STAT’s Bob Herman and J. Emory Parker shows. Leaders of 275 firms collected a combined $3.6 billion, with average compensation topping $13 million. And 91 executives earned at least $10 million, the most since 2021, even as the S&P 500 health care index barely budged and biotech stocks slipped.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
